triple action glp 1 Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and agonists cravings and metabolic efficiency for effortless weight loss without medications. GLP-1-based therapies for type 2

This shift is driven by the parallel global epidemics of type 2 diabetes mellitus (T2DM) and obesity, which fuel the rise of metabolic dysfunction-associated steatotic liver disease (MASLD) (Danpanichkul et al., 2025

Pharmacological treatment of anxiety disorders: the role of the HPA axis

Many patients report: Noticeable increases in energy and recovery within 24 weeks Visible improvements in skin texture and tone within one to two months Continued metabolic and wellness benefits with ongoing therapy Peptide protocols can be adjusted over time for sustained, long-term results

This complex interaction between your gut and brain is what makes GLP-1 so effective in appetite regulation and control, ultimately helping with weight loss

Find articles by Wheeler, M